Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    S&P 500 tumbles 3.7% in worst week since April 2025

    November 21, 2026

    NASA to end Terra satellite mission after decades of work

    November 20, 2026

    Florida flooding rain storm Thanksgiving travel climate hit

    November 19, 2026
    Philadelphia StarPhiladelphia Star
    • Home
    • Contact Us
    • Disclaimer
    • Automotive

      Jaguar Type 01 electric GT debuts with 1,030 PS

      October 7, 2026

      Audi launches Q9 and high performance SQ9 V8 SUV variants

      July 31, 2026

      Ford recalls nearly 420,000 SUVs over seat belt issue

      June 4, 2026

      Mercedes-Benz USA unveils 2027 S-Class with MB.OS tech

      January 30, 2026

      Ford issues US recall for Escape Focus Explorer and Lincoln MKC

      January 22, 2026
    • Business

      S&P 500 tumbles 3.7% in worst week since April 2025

      November 21, 2026

      S&P 500 falls for fourth straight day as Nvidia weighs on stocks

      November 18, 2026

      Brent rises to $93.14 as Gulf attacks keep oil market on edge

      November 18, 2026

      Dollar index climbs to 103.50 as Fed hike bets lift US currency

      November 17, 2026

      Diesel slips to $5.998 a gallon as crude drops and demand eases

      November 16, 2026
    • Entertainment

      Sony confirms God of War trilogy remake and PS5 prequel

      February 13, 2026

      Disney’s Fantastic Four beats Superman in box office debut

      July 27, 2025

      Disney and Marvel’s R-rated film hits billion-dollar milestone

      August 17, 2024

      Web3 leader Immutable rolls out $50M gaming rewards initiative

      April 27, 2024

      USHER’s pre-Super Bowl experience on Apple Music

      February 7, 2024
    • Health

      Mpox cases top 1,000 in Brazil as first 2026 death confirmed

      November 16, 2026

      Together for Science and Health unites 240 groups behind WHO

      November 11, 2026

      Measles surge in US tops 4,580 as Pennsylvania outbreak grows

      October 26, 2026

      Microsoft AI doubles physician accuracy on complex cases

      October 24, 2026

      Walgreens eye drops included in nationwide sterility recall

      October 5, 2026
    • Lifestyle

      Apple and ISSEY MIYAKE unveil new 3D-knit iPhone Pocket

      November 13, 2025

      JP Morgan funds Fresha with $31 million for AI and robotics growth

      August 23, 2024

      Adidas, Highsnobiety debut limited-edition sneakers

      January 6, 2024

      Unraveling Starbucks’ phenomenon as a worldwide coffee powerhouse

      September 1, 2023

      How Nike’s Kobe 8 Protro Halo Marks an Emotional Milestone

      August 29, 2023
    • Luxury

      Price hikes and lack of innovation erode luxury market confidence

      November 18, 2024

      Uncover the allure of Rolex Deepsea – luxury awaits.

      April 10, 2024

      Beyond timekeeping to the prestige of the Rolex Day-Date

      March 2, 2024

      Rare uncut emerald dazzles at Sharjah show

      February 1, 2024

      Porsche and Frauscher launch the electric 850 Fantom Air

      October 17, 2023
    • News

      Florida flooding rain storm Thanksgiving travel climate hit

      November 19, 2026

      Thousands of US flights disrupted by FAA ground stop

      November 14, 2026

      Latvia puts AI and drones on UN Security Council agenda

      November 12, 2026

      Guterres calls Ibero-America a cultural superpower in Madrid

      November 6, 2026

      Democrats flip more than two dozen GOP House seats

      November 5, 2026
    • Sports

      Spain beat Portugal to reach World Cup quarter-finals

      July 7, 2026

      Norway beats Brazil to reach World Cup last eight

      July 6, 2026

      Egypt oust Australia on penalties to reach World Cup last 16

      July 4, 2026

      Spain defeats Austria 3-0 to enter World Cup last 16

      July 3, 2026

      Mexico reaches World Cup last 16 with Ecuador win

      July 2, 2026
    • Technology

      NASA to end Terra satellite mission after decades of work

      November 20, 2026

      Apple iPhone Duo delivers the most cohesive foldable yet

      November 2, 2026

      MacBook Pro gets PROLED XDR screen and Touch on Mac

      October 29, 2026

      Integrated Identity Enters Global Top 0.1% with Rare 100/100 Google PageSpeed

      October 29, 2026

      Meta halts Muse chat links after 6,800 found in DNS records

      October 23, 2026
    • Travel

      Holiday travel airfare deals enter peak booking season

      October 3, 2026

      US keeps Belgium at Level 2 in updated travel advisory

      August 6, 2026

      Maine tourism feels strain as Canadian travel drops

      March 30, 2026

      Houston Bush airport warns of four-hour TSA lines

      March 26, 2026

      U.S. inbound travel declined in 2025 even as global tourism rose

      January 28, 2026
    Philadelphia StarPhiladelphia Star
    Home » FDA grants approval to Cobenfy for schizophrenia management
    Health

    FDA grants approval to Cobenfy for schizophrenia management

    September 29, 2024
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    MENA Newswire News Desk: The U.S. Food and Drug Administration (FDA) has approved Cobenfy, a new medication for the treatment of schizophrenia, marking the first major advance in this area in more than three decades. Cobenfy, developed by Bristol Myers Squibb, is a twice-daily oral medication that combines two drugs, xanomeline and trospium chloride, offering a new therapeutic option for managing schizophrenia symptoms like hallucinations, delusions, and disorganized thinking.

    FDA grants approval to Cobenfy for schizophrenia management

    The FDA’s approval of Cobenfy offers fresh hope for millions of people living with schizophrenia, a severe mental health disorder that affects approximately 24 million people globally. According to Dr. Tiffany Farchione, Director of the Division of Psychiatry at the FDA’s Center for Drug Evaluation and Research, the approval breaks new ground in the treatment of this condition. “This is the first new approach to treating schizophrenia in decades, offering a valuable alternative to the antipsychotic medications that have been standard for so long,” she said.

    Most existing schizophrenia treatments focus on altering dopamine levels in the brain, a neurotransmitter linked to mood and behavior. Cobenfy, however, targets acetylcholine receptors, a different pathway in the brain that influences memory, learning, and attention. This novel mechanism of action is particularly important for patients who experience side effects such as weight gain, drowsiness, or movement disorders from traditional antipsychotics.

    In clinical trials, Cobenfy demonstrated significant effectiveness in reducing schizophrenia symptoms, with only 6% of patients discontinuing the drug due to side effects, compared to 20-30% with older medications. Dr. Samit Hirawat, Chief Medical Officer at Bristol Myers Squibb, hailed the results as a major improvement over previous treatment options.

    Common side effects of Cobenfy include nausea, constipation, and increased heart rate, according to the FDA’s approval notice. However, these side effects were notably less severe than those caused by earlier medications. Dr. Leslie Citrome, a professor of psychiatry at New York Medical College, emphasized that the drug could benefit patients who cannot tolerate the side effects of current treatments.

    Schizophrenia is a lifelong mental illness that typically begins in late adolescence or early adulthood and is characterized by distorted thinking, behavior, and emotions. It often leads to significant challenges in daily functioning, impacting work and relationships. The approval of Cobenfy could represent a breakthrough for patients who have struggled with available treatments for years. Cobenfy is expected to be available for prescription by the end of October, according to Adam Lenkowsky, Executive Vice President at Bristol Myers Squibb. Ongoing studies are also exploring its potential for treating other conditions, including Alzheimer’s disease and bipolar disorder.

    Related Posts

    S&P 500 tumbles 3.7% in worst week since April 2025

    November 21, 2026

    NASA to end Terra satellite mission after decades of work

    November 20, 2026

    Florida flooding rain storm Thanksgiving travel climate hit

    November 19, 2026

    S&P 500 falls for fourth straight day as Nvidia weighs on stocks

    November 18, 2026

    Brent rises to $93.14 as Gulf attacks keep oil market on edge

    November 18, 2026

    Dollar index climbs to 103.50 as Fed hike bets lift US currency

    November 17, 2026
    Latest News

    S&P 500 tumbles 3.7% in worst week since April 2025

    November 21, 2026

    NASA to end Terra satellite mission after decades of work

    November 20, 2026

    Florida flooding rain storm Thanksgiving travel climate hit

    November 19, 2026

    S&P 500 falls for fourth straight day as Nvidia weighs on stocks

    November 18, 2026

    Brent rises to $93.14 as Gulf attacks keep oil market on edge

    November 18, 2026

    Dollar index climbs to 103.50 as Fed hike bets lift US currency

    November 17, 2026

    Mpox cases top 1,000 in Brazil as first 2026 death confirmed

    November 16, 2026

    Diesel slips to $5.998 a gallon as crude drops and demand eases

    November 16, 2026
    © 2026 Philadelphia Star | All Rights Reserved
    • Home
    • Contact Us
    • Disclaimer

    Type above and press Enter to search. Press Esc to cancel.